Contrast-Enhanced Ultrasound In Esophageal Staging

Accurate staging guides treatment for patients with oesophageal cancer. It helps clinicians distinguish disease confined to the oesophageal wall from regional lymph-node involvement or distant spread, supporting decisions about endoscopic therapy, surgery, chemotherapy, radiotherapy, or combined treatment.

Contrast-enhanced ultrasound (CEUS) uses intravenous microbubble agents to show blood flow and tissue perfusion in real time. In selected patients, it can add useful information to endoscopic ultrasound (EUS), computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI).

For Australian clinicians and patients, the technique is most relevant as an adjunct within a specialist multidisciplinary service. Access is more likely in major centres such as Sydney, Melbourne, Brisbane, Perth, and Adelaide than in smaller regional hospitals, where referral pathways and image transfer are important.

How Contrast-Enhanced Ultrasound Works

Ultrasound contrast agents contain gas-filled microbubbles that remain within the bloodstream. When exposed to ultrasound waves, they produce a strong signal from vessels and areas of increased perfusion. This can help identify vascular patterns in a primary tumour or suspicious lymph node.

In oesophageal assessment, contrast may be administered during an EUS examination or during targeted ultrasound of accessible lesions. The examination is performed dynamically, allowing the operator to observe enhancement over time rather than relying only on a static image.

Contribution To Primary Tumour Assessment

EUS remains particularly valuable for evaluating how deeply a tumour has invaded the oesophageal wall. Its close proximity to the lesion allows high-resolution imaging of the mucosa, submucosa, muscular layer, and surrounding tissues.

CEUS may improve visualisation of tumour margins and differences between malignant and normal tissue in selected cases. It can also help distinguish viable, perfused tumour from necrotic areas. These findings may support T-stage assessment, although inflammation, fibrosis, prior biopsy, and operator experience can complicate interpretation.

Regional Lymph Nodes And Microvascularity

Lymph-node involvement is a major factor in oesophageal cancer management. Standard EUS examines node size, shape, border, echogenicity, and internal structure, but these features can overlap between reactive and malignant nodes.

Contrast enhancement adds information about microvascular behaviour. Irregular, heterogeneous, or rapid enhancement may raise suspicion, while a more uniform pattern can support a benign interpretation. CEUS cannot reliably replace tissue sampling, however; EUS-guided fine-needle aspiration or biopsy remains important when the result would change treatment.

Detecting Distant Disease

CEUS is particularly useful for evaluating focal lesions in organs that can be reached with ultrasound, especially the liver. It may characterise a small indeterminate lesion and show arterial and later-phase enhancement patterns that guide further investigation.

Its field of view is limited, so it does not replace contrast CT or PET-CT for a full staging survey. Lung deposits, mediastinal structures, bone disease, and small peritoneal lesions may remain outside its practical range. A multidisciplinary team should interpret CEUS alongside cross-sectional imaging and pathology.

Safety And Australian Practice

Ultrasound microbubble agents do not contain iodinated contrast and are generally not nephrotoxic. This can be useful when renal impairment limits the use of iodinated CT contrast, although the patient’s full medical history still matters. Rare hypersensitivity reactions are possible, and local protocols should address observation and emergency response.

In Australia, use of a contrast agent must align with Therapeutic Goods Administration requirements, product information, credentialling standards, and institutional governance. Consent should cover the intended purpose, alternatives, possible adverse effects, and the fact that CEUS may provide supplementary rather than definitive staging information. Privacy obligations under the Privacy Act 1988 also apply when images are shared between metropolitan and regional services.

Practical Strengths And Limitations

CEUS is most valuable when it answers a focused clinical question that remains after initial imaging. Its portability and real-time capability can be helpful in tertiary hospitals, while rural patients may benefit when a local service can perform targeted imaging before or after referral to a specialist oesophageal unit.

Availability differs across the Australian market. Equipment, trained operators, reimbursement arrangements, and access to approved contrast agents may vary between public hospitals, private radiology practices, and academic centres. Medicare funding should be checked against the specific service and setting rather than assumed.

Useful Clinical Strengths

• Real-time assessment of tumour and nodal perfusion
• Characterisation of selected liver lesions
• No ionising radiation
• Potential value when renal function limits some CT contrast studies

Important Boundaries

• It does not provide complete whole-body staging
• Results depend heavily on operator expertise
• Necrosis and inflammation can mimic malignant patterns
• Suspicious nodes may still require EUS-guided sampling

Selecting Patients And Integrating Results

CEUS should be considered after review of symptoms, endoscopy, biopsy findings, CT or PET-CT, and the proposed treatment pathway. Patients with reflux symptoms, smoking exposure, heavy alcohol consumption, or increasing obesity may present at different stages, but risk factors alone do not determine suitability for the examination.

Australian referral pathways may involve a general practitioner, gastroenterologist, surgeon, medical oncologist, or radiologist. Patients travelling from regional New South Wales, Queensland, or Western Australia may need coordinated appointments to reduce repeated journeys. Clear reporting should state the lesion examined, contrast phase, enhancement pattern, limitations, and recommended correlation with pathology or other imaging.

For practical decision-making, CEUS is best viewed as a targeted enhancement to established staging methods. It can sharpen the assessment of vascularity, selected lymph nodes, and liver lesions, but treatment planning should rest on integrated evidence. The practical takeaway is to use contrast-enhanced ultrasound when it addresses a defined staging uncertainty and to interpret its findings within the full multidisciplinary record.